3272F Medial risk prostate cancer
Also known as: intermediate-risk prostate cancer, moderate-risk prostate cancer, T2b-T3a or Gleason 7
Performance measure for prostate cancer classified as intermediate-risk disease. Quality metric documenting moderate-risk tumor characteristics for prognostic and treatment planning purposes.
In Plain Language
moderately aggressive prostate cancer
Clinical Context
Quality measure used to stratify prostate cancer risk and guide multimodal treatment decisions, typically involving radiation with hormone therapy or surgical intervention.
RVU Information
CPT 3272F does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Documentation should include the clinical indication, service details, and any applicable performance metrics. Coverage may vary by payer — verify acceptance before billing.
Specialties
Frequently Asked Questions
What is CPT code 3272F?
CPT 3272F (Medial risk prostate cancer) is a Other code. Performance measure for prostate cancer classified as intermediate-risk disease. Quality metric documenting moderate-risk tumor characteristics for prognostic and treatment planning purposes.
Who uses CPT code 3272F?
CPT 3272F is used by Urology, Oncology, Quality Reporting. Quality measure used to stratify prostate cancer risk and guide multimodal treatment decisions, typically involving radiation with hormone therapy or surgical intervention.
When is CPT 3272F used?
Quality measure used to stratify prostate cancer risk and guide multimodal treatment decisions, typically involving radiation with hormone therapy or surgical intervention.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.